NCT06923202 Study of Alloknesia in Atopic Dermatitis
| NCT ID | NCT06923202 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Brest |
| Condition | Atopic Dermatosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 160 participants |
| Start Date | 2026-02-10 |
| Primary Completion | 2027-02-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 160 participants in total. It began in 2026-02-10 with a primary completion date of 2027-02-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Alloknesia is defined as pruritus (= itching) triggered by light mechanical stimuli, which are responsible for the perception of light touch under physiological conditions, but which are perceived as pruritic under pathological conditions. Alloknesia occurs mainly in the context of chronic pruritus. Consequently, patients suffering from chronic pruritus frequently perceive light touch sensations as pruritic, which can be particularly unpleasant and alter human interactions and quality of life on a daily basis. However, the epidemiology and burden of alloknesia have never been studied, whatever the cause of chronic pruritus.Atopic dermatitis is one of the main diseases causing chronic itching, and patients frequently complain of alloknesia. In this study, the investigators are studying the frequency of alloknesia in patients with atopic dermatitis and measuring the consequences of alloknesia in these patients.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * No opposition from the patient * Diagnosis of atopic dermatitis more than 6 months old Exclusion Criteria: * Patients who are physically or mentally unable to complete the questionnaires. * Patients on systemic treatment for 1 month or more * Refusal to participate * Patients under legal protection (guardianship, curatorship) * Patients under court protection
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06923202 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atopic Dermatosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06923202 currently recruiting?
Yes, NCT06923202 is actively recruiting participants. Contact the research team at laurent.misery@chu-brest.fr for enrollment information.
Where is the NCT06923202 trial being conducted?
This trial is being conducted at Angers, France, Brest, France, La Roche-sur-Yon, France, Lorient, France and 4 additional locations.
Who is sponsoring the NCT06923202 clinical trial?
NCT06923202 is sponsored by University Hospital, Brest. The trial plans to enroll 160 participants.